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ABSTRACT
In recent years, unprecedented DNA sequencing
capacity provided by next generation sequencing
(NGS) has revolutionized genomic research.
Combining the Illumina sequencing platform and a
scFv library designed to confine diversity to both
CDR3, >1.9 10
7 sequences have been generated.
This approach allowed for in depth analysis of the
library’s diversity, provided sequence information
on virtually all scFv during selection for binding to
two targets and a global view of these enrichment
processes. Using the most frequent heavy chain
CDR3 sequences, primers were designed to
rescue scFv from the third selection round.
Identification, based on sequence frequency,
retrieved the most potent scFv and valuable
candidates that were missed using classical
in vitro screening. Thus, by combining NGS with
display technologies, laborious and time consuming
upfront screening can be by-passed or comple-
mented and valuable insights into the selection
process can be obtained to improve library design
and understanding of antibody repertoires.
INTRODUCTION
In vitro display technologies have provided a powerful
means for generating and evolving proteins with novel
properties. In most cases, the aim of such approaches
has been to isolate novel binding speciﬁcities from
peptides, antibody fragments or alternative scaffold
protein repertoires (1–5). For the past two decades,
phage display has been an invaluable technology for
in vitro evolution and identiﬁcation of peptides and
proteins (6–9). Despite the development of alternative
display technologies, such as bacterial display, yeast
display and ribosome display, the robustness of ﬁlament-
ous bacteriophage M13 makes it one of the most widely
used approaches for academic centers as well as the bio-
pharmaceutical industry. For instance, libraries of
antibody fragments displayed on phage have delivered
several fully human monoclonal antibodies that are cur-
rently in clinical trials, proving the signiﬁcant contribution
of phage display to the success of this class of therapeutic
molecules (6,10–13).
In vitro display and selection approaches involve three
main steps: (i) the generation of a large collection of
variants (a library); (ii) multiple rounds of enrichment of
variants having the desired properties via the genotype–
phenotype linkage provided by the display system used;
and (iii) functional screening and characterization of
selected variants using appropriate assays. At each of
these steps, analysis of variants via Sanger sequencing
is commonly used to control the process and identify
sequences of interest. In recent years, the development
of next generation sequencing (NGS) technologies has
revolutionized multiple aspects of biological research
(14–16). These sequencing platforms also have the poten-
tial to profoundly impact the display and selection process
of proteins with desired properties as follows.
At the library generation stage, it is crucial to cover as
much sequence and structural diversity as possible to
increase the likelihood of including protein variants with
desired properties. The diversity of phage display libraries
typically lies between 10
7 and 10
11 (17). Sequencing several
hundred members from the library is usually performed to
evaluate the number of clones that are different and in the
correct reading frame, reﬂecting the diversity and quality
of the library. A major limitation using Sanger sequencing
is that only a minute fraction of the library is actually
sampled (a few hundred at best, out of >10
7 clones).
The large number of sequencing reads delivered by NGS
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6) is in principle ideally suited for the
analysis of vast numbers of library members and a much
more extensive evaluation of library diversity and quality.
Similarly, during enrichment via multiple selection
rounds, sequencing of a limited number of clones only
provides a glimpse into the enrichment process and is
only used to determine which selection round should be
used for the screening step. The capacity to obtain
sequence information on far more if not all clones at
each round would offer a virtually comprehensive
analysis of the selection process, potentially rendering
the screening step unnecessary.
NGS has recently been applied to analyze of the im-
munoglobulin repertoires of zebraﬁsh and humans (18–
20). The sequence diversity of immunoglobulins
captured from natural repertoires is spread across the six
complementary determining regions (CDR) of the heavy
and light chain variable domain. Therefore, relatively long
reads (i.e. >300 bases) are needed to cover the entire
sequence of an immunoglobulin variable domain and
require the use of pyrosequencing. However, although
producing longer reads, pyrosequencing is currently
limited to 10
6 reads per run while other technologies can
deliver >10-fold more reads albeit of much shorter lengths
(30–100 bases) (15). Therefore, in this study, we applied
the Illumina sequencing platform to a specially designed
scFv library. Our approach allowed for the in-depth
analysis of the library, extensive coverage of sequences
at each selection round and ability to follow enrichment
during two independent selection processes. Based solely
on sequence information, we isolated target speciﬁc
antibody fragments including some that were missed.
Taken together our approach demonstrates a powerful
combination which can completely by-pass the need for
a primary screening step.
MATERIALS AND METHODS
Library construction
Human VH and VL germlines were ampliﬁed from
human genomes of Jurkat, HeLa and HEK 293 cells
from NEB by PCR. The fragments were extended by
PCR (Supplementary Data) to introduce a CDR3
stuffer, a human FR4 sequences and the restriction
sites NcoI/XhoI for VH and SalI/NotI for VL. These
restriction sites were used for cloning into the
phagemid vector pNDS1. The pNDS1 vector that was
derived from pHEN1 phagemid vector (21). The
cloning site contains a (Gly4Ser)3 linker sequence
ﬂanked by the restriction enzyme sites NcoI/XhoI for
VH cloning and SalI/NotI for VL cloning. The NotI
site is followed by a hexahistidine tag, a c-myc tag and
an amber stop codon. The CDR3 stuffers introduce a
frameshift impairing the expression of any functional
scFv. The stuffers do also contain two BsmBI restriction
sites for the cloning of diversiﬁed CDR3 sequences. The
synthetic CDR3 diversity was generated by PCR
assembly using degenerated oligonucleotides (see
Supplementary Data) with codons NNS, DVK, NVT
or DVT depending on the CDR3 length. The CDR3
were randomized on 4–10 residues. The resulting cas-
settes create synthetic diversity both in CDR3 sequence
and length. As the oligos were biotinylated (Microsynth)
the digested inserts were puriﬁed using StreptaBeads
(Dynal). After a phenol/chloroform extraction step,
they were precipitated with ethanol and resuspended in
H2O. Using BsmBI (NEB) restriction enzyme Type IIS
the synthetic diversity was introduced into the respective
VH and VL acceptor vectors without any change in
the framework sequences. The VH and VL sublibraries
were recombined using XhoI/NotI restriction sites.
Recombinant pNDS1 was electroporated into
Escherichia coli TG1 cells.
Phage selections
TG1 cells were grown at 37 C (240rpm) in 2xTYAG
(100mg/ml ampicillin, 2% glucose) medium. At
OD600=0.4–0.5 the AE1 library was rescued by
super-infection with M13K07 helper phage for 1h at
37 C (100rpm). Culture medium was then changed for
2xTYAK (100mg/ml ampicillin, 50mg/ml kanamycin) and
TG1 were grown o/n at 30 C (280rpm). Phage were
puriﬁed and concentrated from the culture supernatant
by two precipitations with one-third v/v of 20%
PEG-8000/2.5M NaCl (Sigma) and resuspended in TE
buffer, dialyzed against TE buffer and titrated by infect-
ing TG1 cells. Phage (10
12 pfu) were blocked with phos-
phate buffered saline (PBS) containing 3% (w/v)
skimmed milk and deselected on immunotubes (Nunc)
coated with a rat IgG2b isotype antibody for selections
against 5E3 and on streptavidin coated magnetic beads
(Invitrogen) for selection against human interferon g
(hIFNg). Deselected phage were incubated for 2h (RT)
in either immunotubes coated with 10mg/ml of the
anti-mouse TLR4 rat monoclonal antibody 5E3 or with
Streptabeads (Invitrogen) coated with 200nM
biotinylated hIFNg. Non-speciﬁc phage was eliminated
by ﬁve washes with PBS/0.1% Tween-20 and two
washes with PBS. Bound phage were eluted with
10mM triethylamine TEA (Sigma), neutralized with
1M Tris–HCl pH 7.4 (Sigma). The eluate was added to
10ml of exponentially growing E.coli TG1 cells and
incubated for 1 h at 37 C (100rpm). An aliquot of the
infected TG1 was serial diluted to titer the selection
output. The remaining infected TG1 were spread on
2xTYAG agar Bioassay plates. After overnight incuba-
tion at 30 C, bacteria were scraped off with 2xTY
medium and aliquots were stored at  80 C in 17%
glycerol. For subsequent rounds of panning 10
10 pfu
were used.
Sequencing using the Illumina platform
For the VH, we used FR4 speciﬁc (50-CCTGGCCCCAAT
AATC-30) and M13Rev primers (50-AACAGCTATGAC
CATG-30) to prepare initial PCR products on which the
Genome Analyzer adapters were added in two 5 cycles
PCR steps using the Phusion polymerase (Finnzymes):
The ﬁrst ampliﬁcation added the Illumina Genomic
Sequencing primer sequence (SBS) and a four bases
bar-code to the 50-side of FR4 and the Illumina P7
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liﬁcation completed the library construction with a primer
adding the Illumina P5 sequence 50 to the SBS end and a
P7 primer. A similar approach was used for the VL, either
on the original libraries or on the same FR4/M13Rev
initial PCR products. The two step addition of the
Genome Analyzer P5-SBS or P7 sequences occurred on
the 50-side of nested primers 50-ATGATGATGTGCGG
C-30 or 50-TTAGATTATTGGGGCCAGG-30, respec-
tively. Cloning a 1ml aliquot of the puriﬁed ﬁnal
products into a pCR-TOPO-Blunt plasmid and capillary
sequencing eight clones controlled the quality of the
Genome Analyzer-ready libraries.
The VH bar-coded libraries were sequenced on
a Genome Analyzer GAII instrument following
Illumina’s standard procedures, with cluster generation
kit v. 2.0 and sequencing kits v.3.0, multiplexed in one
single-reads channel for 76 cycles. The base-calling
was performed using the GAPipeline 1.4.0. The VL
bar-coded libraries were sequenced on the same instru-
ment, but with cluster generation kit v. 4.0 and
sequencing kits v. 4.0, multiplexed in one single-reads
channel for 76 cycles. Base-calling was performed using
the GAPipeline 1.5.1. In all cases, the run quality is
monitored using a standard procedure from Illumina,
which is to analyze a control DNA supplied by the
manufacturer and determine the error rate of the result-
ing sequences.
Screening ELISA
Individual clones were grown in 2xTYAG medium in
96-well plates. scFv expression was induced with IPTG
(1mM) overnight at 30 C (150rpm). The supernatants
containing scFv were used in ELISA to evaluate their
binding speciﬁcity and afﬁnity on 5E3. The 96-well
MaxiSorp plates (Nunc) were coated overnight (4 C)
with 50ng/well of 5E3 or a rat isotype antibody. The
supernatants and the assay plates were blocked with
PBS/3% milk for 1h (RT). After washing the assay
plates three times with PBS/0.05% Tween-20, 50mlo f
the blocked supernatants containing scFv were transferred
to the wells and incubated 2h at RT. Binding scFv were
detected with mouse anti-cmyc and anti-mouse IgG
Fcg-HRP antibodies. The assay was developed with
TMB substrate (Sigma) and the reaction stopped with
H2SO4 2N and the absorbance read at 450nm.
VHCDR3 based rescue
Sense and anti-sense primers speciﬁc for the VHCDR3 were
used in combination with M13Fwd and M13Rev primers
on 15ng of template DNA from TG1 cells obtained after
Round 3. The two resulting DNA fragments were
assembled by PCR, digested with NcoI and NotI,
ligated into pNDS1 and transformed into TG1 cells.
Minipreps of the resulting transformation were sequenced
by Sanger sequencing. Their sequences were aligned using
the Sequencher vs.4.8 (Gene Codes) software.
RESULTS
Generation of a scFv library with diversity restricted
to CDR3
The two complementary determining regions 3 (CDR3) of
an immunoglobulin molecule form the center of the
antigen combining site and, although the other comple-
mentary determining regions (CDR) often contribute to
the binding energy, diversiﬁcation of the CDR3 regions is
sufﬁcient to generate antigen speciﬁc antibodies (22–24).
Thus we have generated a library of human scFv based on
a limited number of human immunoglobulin variable
genes in which diversity was introduced only in CDR3
of the heavy and light chains. Seven human germline
genes were selected for both the heavy and light chain
variable regions (VH1-2, VH1-18, VH1-69, VH3-30.3,
VH3-48, VH3-23, VH5-51, VK1-33, VK1-39, VK3-11,
VK3-15, VK3-20, VL1-44, VL1-51; nomenclature accord-
ing to the IMGT database) based on their frequency in
natural human repertoire, their stability as well as having
different CDR1 and CDR2 sequences in order to include
some germline encoded diversity in these regions. At the
30-end of the variable genes, a DNA sequence that
contains two BsmBI restriction sites was introduced,
changing the reading frame so that the resulting construct
cannot encode a functional immunoglobulin variable
region. These heavy and light chain ‘acceptor frameworks’
were used to introduce diversiﬁed sequences via Type IIS
restriction cloning, restoring the correct reading frame of
an antibody variable region (Figure 1A). Diversiﬁed se-
quences encoding heavy chain CDR3 of 9–15 amino acids
in length (according to the IMGT deﬁnition of CDR) were
introduced into the seven VH acceptor frameworks (25).
Similarly CDR3 of 8–11 amino acids were cloned into the
VL acceptor frameworks. A ﬁnal library of 7 10
9
transformants, named AE1, was obtained by combining
the diversiﬁed heavy and light chain variable regions into
the phagemid vector pNDS1, allowing for scFv expression
and display at the surface of M13 ﬁlamentous bacterio-
phage (7).
Next generation sequencing of the antibody library and
selection rounds
The AE1 library was used for the identiﬁcation of
anti-idiotype scFv fragments directed against the rat
anti-mouse TLR4 monoclonal antibody, 5E3 (26). Three
rounds of selection were performed using a classical
panning approach against 5E3 immobilized on
immunotubes. At each round, the input phage was ﬁrst
deselected against another immobilized rat antibody of the
same isotype (IgG2b) in order to drive the selection
towards the variable regions of 5E3.
Currently, the Illumina sequencing platform generates
reads of about 76bp (15). The oligonucleotide primers in
our study were speciﬁc to a region common to all clones
in order to avoid biases. For the heavy chain, the primer
was speciﬁc for FR4 and the sequencing read covered the
whole CDR3 and in most cases provided enough FR3
sequence information to identify the VH family
(Figure 1A). As the   and k light chains have different
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further downstream in the vector sequence. Therefore,
the sequences unambiguously identiﬁed k from   light
chains but only partially covered the CDR3 sequence
(Figure 1A). Phagemid DNA was isolated from the
AE1 library and bacteria recovered after each round of
selection. The scFv coding regions were then ampliﬁed
using primers introducing a 4-nt sequence tag allowing
for simultaneous solid phase sequencing of DNA frag-
ments from the library as well as different selection
rounds with the same Illumina channel. The heavy and
light chain CDR3 regions were sequenced in two inde-
pendent runs and samples from the library and each
round were mixed in a 7:1:1:1 ratio in order to obtain
a maximum number of reads from the more diverse
library while covering the diversity of each selection
round. A total of 6635657 and 8896028 reads were
obtained for heavy and light chain runs, respectively,
representing more than one billion bases sequenced
(Table 1).
Table 1. Summary of NGS results for the heavy and light chains
AE1 library (%) Round 1 (%) Round 2 (%) Round 3 (%)
Selection on 5E3
VH(FR3-CDR3-FR4)
Total number of sequences 5078705 352778 561296 642878
Unique sequences 5007022 (99) 124909 (35) 130382 (23) 105011 (16)
Single occurrence sequences
a 4938237 (99) 89523 (72) 103009 (79) 82525 (79)
Repeated sequences
b 68785 (1) 35386 (28) 27373 (21) 22486 (21)
Highest frequency 42 (0) 1439 (0.4) 9870 (2) 37017 (6)
Identiﬁed VH family
c 4680882 (92) 332201 (94) 538706 (96) 619707 (96)
In frame inserts
d 4237321 (91) 322273 (97) 527932 (98) 612130 (99)
VL(CDR3-FR4)
Total number of sequences 4412636 1531261 1302154 1649977
Unique sequences 3612120 (82) 733282 (48) 493490 (21) 576062 (19)
Identiﬁed VL group
e 4051197 (92) 1470871 (96) 1269674 (98) 1597046 (97)
Selection on IFNg
VH(FR3-CDR3-FR4)
Total number of sequences 1176998 1484395 1247375
Unique sequences 1075049 (91) 167900 (11) 67936 (5)
Single occurrence sequences
a 1008532 (91) 109445 (65) 50841 (75)
Repeated sequences
b 66517 (6) 58455 (35) 17095 (25)
Highest frequency 13139 (1) 19571 (1) 112452 (9)
Identiﬁed VH family
c 1133917 (96) 1426351 (96) 1234160 (99)
In frame inserts
d 1039842 (92) 1314621 (92) 1233561 (100)
aSingle occurrence sequences: number of sequences occurring a single time in the set of unique sequences.
bRepeated sequences: number of sequence occurring a multiple times in the set of unique sequences.
cIdentiﬁed VH family: number of single occurrence sequences for which FR4 information allowed unambiguous VH family identiﬁcation.
dIn frame inserts: number of sequences with an identiﬁed VH family that contain an in frame insertion.
eIdentiﬁed VL group: number of sequence that could be unambiguously identiﬁed as k or   based on FR4 sequence.
A
B
Figure 1. Schematic representation of immunoglobulin heavy and light chain variable regions and CDR3 diversiﬁcation strategy. (A) Framework
regions (FR1 to FR4) and CDR regions (H1 to H3 and L1 to L3) are indicated. Stars indicate the location of Type IIS restriction sites in the stuffer
fragment located between FR3 and FR4 and in the ﬂanking regions of the diversiﬁed VHCDR3 and L3. The sizes of the designed VHCDR3 and L3 are
9–15 and 8–11 amino acids, respectively. The arrows indicate the location of the primers used for next generation sequencing and the dashed arrows
indicate the region covered by the 76bp reads. The heavy chain primer, which is located in the FR4 region, permits partial sequencing of the FR3
region (VHFR4-CDR3-FR3). In contrast, as the light chain primer is located downstream of the FR4 region, the sequencing read does not cover the full
CDR3 sequence (VLCDR3-FR4). (B) ScFv rescue strategy based on VHCDR3 sequences. Arrows indicate complementary primers corresponding to a
VHCDR3 sequence as well as primers ﬂanking the scFv coding region. These primers were used to amplify and assemble the scFv sequence from the
pool of clones following the third selection round.
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Next, the efﬁciency of our CDR3 diversiﬁcation strategy
was evaluated by analyzing over ﬁve million reads
covering the VHFR3-CDR3-FR4 region of the scFv
(Table 1). Over 98.5% of the sequences were unique and
98.6% of those were a single copy in the library. A far
smaller number of sequences were found in multiple copies
and the most frequent sequence was found 42 times. A
total of 92% reads could be attributed to a VH germline
family and revealed that the VH1, VH3 and VH5 families
were relatively equally represented (Figure 2A). From the
sequences in which a sufﬁcient length of the FR4 sequence
could be obtained (allowing for a VH family assignment
and an accurate reading frame determination) 91% of
inserts were inframe (Table 1). Furthermore, the CDR3
lengths and distribution corresponded to the library’s
design although CDRs of 13 amino acids were slightly
underrepresented (Figure 3A).
The analysis of the reads covering the VLCDR3-FR4
region conﬁrmed the expected 5:2 k/  ratio and the high
diversity of the library with at least 82% representing
unique sequences (Figure 2B, Table 1). This number
underestimates the diversity as a fraction of the CDR3
sequences were not fully covered by the 76-bp reads
(Figure 1A). Thus, high throughput sequence analysis
demonstrated that our library construction strategy
generated a high percentage of diverse and in frame
coding sequences. As the high throughput sequencing
data probed a limited portion of the scFv sequence, we
conﬁrmed these ﬁndings by full length Sanger sequencing
of 132 randomly picked library members (data not
shown).
Sequence evolution during phage selection against 5E3
During the selection of phage binding to the target, 5E3,
the number of phage particles recovered after the ﬁrst,
second and third rounds was 1.8 10
5, 3.4 10
5 and
1.1 10
6, respectively. Therefore, as the maximal
number of different sequences present at later selection
rounds is limited by the output of the ﬁrst round and in
this case lies in the 10
5 range. Using NGS, between
3.5 10
5 and 6.4 10
5 reads for the VH and>10
6 reads
for the VL were obtained for each selection round
(Table 1). As such, this very large fraction of clones
8% 6%
81% 94% 84% 75%
A
VH1
VH3
VH5
29% 16%
R1
21%
9%
4% R2
38%
Lib.AE1
20% 11%
4% R3
VH
Undetermined
49% 66% 27%
27%
65%
B
V kappa
V lambda
Udt i d
15%
4% R1
4%
2% R2
13%
3% R3
17%
8%
Lib.AE1
VL
Undetermined
VH1
18%
1% R3 4 % R2 4 % R1 Lib.AE1
VH C
VH3
VH5
Undetermined 59% 22%
42 %
31 %
23 %
43 %
27 %
26 %
38 %
27 %
27 %
8 %
Figure 2. Germline gene family analysis. (A) Frequency of heavy chain variable gene families identiﬁed and (B) proportion of V k and V   light
chains in the AE1 library and after each selection round (R1–R3) against the target, 5E3. (C) Frequency of heavy chain variable gene families
identiﬁed in the AE1 library and after each selection round (R1–R3) against the target, hIFNg. Sequences were considered as undetermined if they
did not match exactly the signature sequence used for family assignment.
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of the frequency and evolution of individual VH and VL
sequences throughout the process.
Next, assessing VH germline genes, VH3 signiﬁcantly
increased from 27% (in the AE1 library) to 65% (after
the third round of selection, Figure 2A). This result was
not unexpected as VH3 genes encoded antibody fragments
have been shown to be well tolerated in display settings and
are often used for the generation of semi-synthetic libraries
(23,24,27). The k to   ratio remained relatively unchanged
throughout the selection process although a reduced fre-
quency of   chains was observed after the second round
(Figure 2B). The distribution of VHCDR3 lengths changed
during the selection process with an enrichment of CDRs
of 11 amino acids or more and a marked reduction in
CDRs of 9 and 10 residues (Figure 3). Clones containing
out of frame VHCDR3 and therefore encoding
non-functional scFv, were lost during selection (Table 1,
Figure 3). Interestingly, VHCDR3 of eight amino acids were
enriched after the ﬁrst selection round and reached 10%
after the third round (Figure 3D). As the shortest VHCDR3
design in the library was nine amino acids in length, these
sequences were not theoretically included in the library.
Therefore they are probably generated due to errors
occurring during oligonucleotide synthesis or are cloning
artifacts ( 9%, Table 1).
We also followed the enrichment proﬁle of the 10 most
frequent VHFR3-CDR3-FR4 sequences at Round 3 which
were present in a range between 37017 and 2815 times
(Figure 4A). In most cases, the major enrichment was
observed after the third round of selection except for
sequence #3 which was more gradually enriched and
already the most abundant after Rounds 1 and 2
(Figure 4A). These 10 top sequences accounted for
>17% of all sequences after Round 3 and the three
most abundant represented 14% suggesting that these
should be readily identiﬁed during screening for binding
to the target.
Hit identiﬁcation by classical primary target binding
screening
As classically performed in a phage selection program, 96
individual clones from the third round of selection were
picked and scFv secretion into the medium induced in
order to screen by ELISA for speciﬁc binding to the
target, 5E3. Positive clones were sequenced and grown
in larger volumes in order to purify the scFv and
conﬁrm their speciﬁcity in dose response experiments.
Six scFv were identiﬁed having a binding EC50 in the
nanomolar range for 5E3 versus a control protein
(Figure 5). We next determined the frequency of the
VHFR3-CDR3-FR4 and VLCDR3-FR4 sequences of these
clones in the AE1 library and selection rounds. As
expected, these sequences were enriched during selection
and maximal frequencies of 2–6% were observed after the
third rounds for the scFv D11 and D6 (Figure 5). These
two clones also had the highest apparent binding afﬁnity
in the dose response ELISA indicating that the selection
process, based on binding to a target, indeed enriched
for phage having a high afﬁnity for the target (Figure 5).
The parallel increase in frequency of VHCDR3 and VLCDR3
of each clone suggests that it is due to the enrichment of
the selected clone carrying both CDR3 sequences (Figure
5). However, as the light and heavy chain sequence infor-
mation was generated independently, we cannot exclude a
contribution of clones carrying only one of the CDR3 (i.e.
VHCDR3 or VLCDR3) in combination with a different
sequence.
ScFv rescue via VHCDR3 ampliﬁcation
The VHFR3-CDR3-FR4 sequences of the six scFv identiﬁed
by screening could all be identiﬁed in the sequencing data
and their respective frequencies after the third round of
selection determined (Figure 5). The sequences corres-
ponding to clone D11, D6 and D4 were found among
the 10 most frequent sequences and D11 that has the
highest apparent afﬁnity was also the most enriched
during selection (Figure 4). However, several sequences,
frequently found after Round 3, were not identiﬁed during
the ELISA screening. In particular, clone #2 representing
the second most abundant sequence with close to 6% of
all sequences at Round 3, had not been identiﬁed
(Figure 4). We wanted to understand whether these
clones had been missed because of the limited number of
scFv that were tested or if there were some characteristics
that prevent their identiﬁcation by an ELISA screening
approach. We therefore aimed at rescuing scFv bearing
the six most frequent VHCDR3 sequences by PCR ampli-
ﬁcation. These included three scFv identiﬁed by screening
(5E3R-1, 5E3R-3 and 5E3R-6) as well as three scFv that
had not been identiﬁed (5E3R-2, 5E3R-4 and 5E3R-5,
Figure 4A) Complementary pairs of oligonucleotides
primers speciﬁc for these six VHCDR3 were designed and
used in combination with primers located upstream and
downstream of the scFv coding region in order to recover
from the output of Round 3 the complete scFv sequence,
or sequences, bearing these frequent VHCDR3 (Figure 1B).
The ampliﬁcation products were cloned into the pNDS1
vector and 10 independent clones for each rescued scFv
were sequenced. All clones contained the same pair of
VHCDR3 and VLCDR3 further suggesting that the
observed parallel enrichment of two VHCDR3 and
VLCDR3 sequences was mainly due to the enrichment of
a single clone and not of various scFv bearing a VHCDR3
in combination with a variety of VLCDR3 sequences.
These six rescued scFv were expressed and tested for
binding to the target, 5E3 using ELISA but with different
formats. We ﬁrst performed an ELISA using phage dis-
playing the scFv at its surface to test the binding in the
same context as during the selection process. Binding of
secreted scFv was also tested using bacterial supernatant
or periplasmic fractions, the latter preparation providing a
more concentrated source of crude scFv. Finally, each
clone was expressed at a larger scale and puriﬁed from
the periplasmic space using immobilized metal ion chro-
matography, quantiﬁed and veriﬁed on SDS–PAGE for
integrity and purity. The puriﬁed scFv were then used in
dose-response experiments to determine their apparent
binding afﬁnity. The results from these experiments
using different formats and sources are summarized in
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phage in agreement with their enrichment during the se-
lection process. In contrast, only the 5E3R-1, 5E3R-3 and
5E3R-6 scFv gave a positive signal using crude super-
natants or periplasmic preparations providing an explan-
ation to why the 5E3R-2, 5E3R-4 and 5E3R-5 clones were
not identiﬁed during the screening step. These three scFv
were probably not well expressed or secreted as reﬂected
by the lower yield obtained after large scale production
(Table 2). Interestingly, 5E3R-4 and 5E3R-5 bound 5E3 in
scFv format with EC50 of 2.3 and 140nM, respectively. As
a soluble scFv, 5E3R-2 did not give any signal, suggesting
that it requires the phage context for binding to the target.
These results indicate that by using a rescue approach
based on VHCDR3 sequence frequency, we retrieved the
best scFv candidates identiﬁed by ELISA approach and,
6%
VH CDR3 Round 3 Rescued Corresponding
Clone # Sequence (IMGT) screening hit
A
Selection on 5E3
3%
4%
5%
e
n
c
y
Clone # Sequence (IMGT) Length Family frequency clones screening hit
1 ARGNRRAYMDY 11 VH1 37017 5E3R-1 D11
2 ARGTYANTTSMDY 13 VH5 36901 5E3R-2
3 ARGDSNTDDADAMDY 15 VH3 14096 5E3R-3 D6
4 ARGRKKEKGMDY 12 VH3 7661 5E3R-4
-
1%
2%
F
r
e
q
u 5 ARGRPSLFDY 10 VH1 5573 5E3R 5
6 ARGRRTGGMDY 11 VH5 3290 5E3R-6 D4
7 ARSAGMDY 8 VH3 3159
8 ARDSRDGTPMDY 12 VH3 2867
9 ARRKKMDY 8 VH3 2818
0%
Lib. AE1 R1 R2 R3
VH CDR3 R d 3 R d
10 ARDAPTGDPFDY 12 VH1 2815
B
Selection on IFNg
6%
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c
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VH CDR3 Round 3 Rescued
Clone # Sequence (IMGT) Length Family frequency clones
1 ARETDSWDTFDY 12 VH1 112452 IFNR-1
2 ARGGWATKFDY 11 VH1 26872 IFNR-2
3 ARYTYHPDGGDMDY 14 VH5 25199 IFNR-3
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4%
5%
F
r
e
q
u
e
n
4 ARGSFSLMDY 10 VH3 23608 IFNR-4
5 ARYGYTASNSGAMDY 15 VH5 19892 IFNR-5
6 ARGSGYYTAGSFDY 14 VH5 17325 IFNR-6
7 ARGYWSASFDY 11 VH1 17004 IFNR-7
8 ARGWWSSNFDY 11 VH1 16001 IFNR-8
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1%
Lib.AE1 R1 R2 R3
9 ARGHDRRSGDFDY 13 VH5 15896 IFNR-9
10 ARGGWGASFDY 11 VH1 14459 IFNR-10
Figure 4. Frequency and evolution of top 10 sequences. Frequency of the 10 VHCDR3 sequences that were the most abundant after the third
selection round against 5E3 (A) and against hIFNg.( B) Amino acid sequence, length of the VHCDR3 according to the IMGT nomenclature and VH
family are shown. Sequences that were also identiﬁed during screening by ELISA as well as clones that were rescued based on their VHCDR3 sequence
and frequency are indicated.
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Figure 5. Frequency and evolution of CDR3 sequences identiﬁed by classical binding screening against the target 5E3. Frequency evolution of
VHFR4-CDR3-FR3 (A) and VLCDR3-FR4 (B) sequences corresponding to six scFv binding speciﬁcally to the monoclonal 5E3. The EC50 for binding of
the soluble scFv to the target in ELISA and the frequency ranking after the third round of selection are indicated below each clone.
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dates that were missed using a classical screening
approach.
Bypassing primary screening
In order to further validate the approach, we applied the
same procedure against another target. We performed
three rounds of phage selection using the AE1 library
against soluble biotinylated hIFNg. The output of each
round was sequenced and over 1 million reads covering
the VHFR3-CDR3-FR4 region were obtained for each output.
As expected, the number of unique sequences diminished
and the frequency of repeated sequences increased to
reach 25% after the third selection round indicating that
selection had occurred (Table 1). The VH families could
be identiﬁed for >95% of the sequences and, in this case, a
clear enrichment for VH1 was observed (Figure 2C).
Similarly, the VHCDR3 lengths distribution was different
compared to that observed during selection against 5E3,
thus indicating that different CDR lengths were
preferentially enriched in a target dependent manner
(Figure 3E–G). We then rescued the 10 most frequent
clones after the third round by overlapping PCR using
primers matching their respective VHCDR3 sequences
(Figure 4B). These rescued scFv were expressed in
soluble form or displayed at the surface of ﬁlamentous
bacteriophage to characterize their binding properties.
All the candidates were able to bind hIFNg in a speciﬁc
manner using phage or puriﬁed scFv (Table 2). However,
four candidates (IFNR-1, 2, 8 and 9) did not give any
signal when supernatants or periplasmic preparations
from 96-well plates were tested in ELISA, indicating
that these candidates would not have been identiﬁed in a
primary screening step. This second example further
demonstrated that antibody candidates can be retrieved
without upfront screening of randomly picked clones. In
addition, a signiﬁcant proportion of the most enriched
clones (4 out of 10), that would have been repeatedly
screened given their high frequency but missed by a
standard screening approach, could be identiﬁed by this
approach.
DISCUSSION
In only a few years, the emergence of NSG technologies
has profoundly modiﬁed the landscape of whole genome
analysis as well as gene expression proﬁling and will cer-
tainly impact many other areas of research (15). The large
amount of sequencing data delivered by these platforms is
ideally suited for extensive analysis of complex collections
of diversiﬁed gene segments such as antibody or peptide
libraries. The currently available platforms that are
capable of providing several million reads per run,
generate only short reads of up to 100bp (15). We there-
fore combined a synthetic scFv library, containing diver-
sity conﬁned to VHCDR3 and VLCDR3, with the Illumina
NGS platform. We generated over 9 million reads
covering the diversiﬁed CDR3 and, although only 0.22%
of the library members were sampled, it is the most exten-
sive sequence analysis of an antibody library reported to
date. Furthermore, we demonstrated the effectiveness of
our library building strategy via a Type IIS restriction
enzyme cloning, resulting in >90% of in frame inserts,
which is superior to several described library construction
methods (28–31).
For the ﬁrst time, we illustrate that it is possible to
follow the evolution of virtually all VHCDR3 and
VLCDR3 sequences during a phage display selection
process. By comparing the sequences of hits identiﬁed by
ELISA screening with VHCDR3 and VLCDR3 frequencies,
we found that apparent binding afﬁnity and enrichment
correlated for several clones. However, it was clear that
some highly enriched clones were missed during primary
screening and the antibodies encoded by these ‘lost’ clones
were valuable candidates.
In recent years, much effort has been spent in order to
improve in vitro evolution approaches by optimizing or
simplifying each step (i.e. library generation, selection
and screening). For instance, it has been shown that selec-
tion rounds can be drastically reduced—and potentially
even skipped—using high-throughput antibody array
screening (32). Here, using the capacity of a NGS
platform, it is feasible to completely by-pass primary
screening, focusing on the most frequent sequences to
proceed directly to in depth characterization in more
relevant assays. Furthermore, target speciﬁc scFv that
were not identiﬁed via a classical ELISA screening could
be identiﬁed based on their frequency. All the scFv
described in this study are capable of binding to the
target when displayed on phage and give positive signals
in phage ELISA (Table 2). This is expected as they were
enriched during the phage selection process which is
driven by binding to the target. However, a signiﬁcant
proportion of clones were negative in classical soluble
scFv ELISA screening because the suboptimal growth
conditions of a microtiter plate format do not support
sufﬁcient expression of these scFv. In contrast, we
showed that all the clones rescued, based on sequencing
Table 2. Binding experiments for scFv displayed on the surface of
phage or expressed in different soluble formats
scFv Phage scFv
Supernatant
scFv
Periplasmic
fraction
Puriﬁed
scFv
EC50 (nM)
scFv-yield
(mg/l)
5E3R-1 + + + 1.9 5
5E3R-2 + –    0.25
5E3R-3 + + + 2 2.2
5E3R-4 +    2.3 0.34
5E3R-5 +    140 0.21
5E3R-6 + + + 3.6 0.4
IFNR-1 +   37.9 5
IFNR-2 +   41.0 13.4
IFNR-3 + + + 1.3 1.7
IFNR-4 + + + 0.16 10.6
IFNR-5 + + + 1.4 0.2
IFNR-6 + + + 0.75 6.3
IFNR-7 + + + 0.36 2.9
IFNR-8 +    139.3 16
IFNR-9 +    4.7 7.5
IFNR-10 + + + 0.1 23.8
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soluble scFv from larger culture volumes with more
optimal aeration and growth conditions. Furthermore,
the large majority of these puriﬁed scFv were positive in
dose response ELISA with IC50 in the nanomolar range
(Table 2). The capacity to identify more candidates from a
selection process is signiﬁcant as it is important to recover
a wide diversity of scFv to maximize epitope coverage on
the target protein in order to bind functionally relevant
epitopes, regardless of the initial afﬁnity of the scFv.
This approach also signiﬁcantly streamlines projects by
removing the need for developing robust screening assays
that must be designed and optimized for each target
whereas the procedure for NGS will be the same for any
target being considered. Laboratories tend to increase
their screening capacity to be able to evaluate a
maximum number of clones. This involves acquisition
and time consuming implementation of expensive
robotic and liquid handling equipment (33). It is obvious
that random picking of clones for screening leads to the
repetitive testing of scFv that have been the most enriched
and thus a signiﬁcant waste in terms of screening capacity.
In contrast, comprehensive sequencing after enrichment
directly provides information on all potential candidates.
Here we have used frequency as a very simple method to
select clones for rescue and characterization, but more
elaborate sequence analysis including CDR length and
amino acid composition should allow clustering of se-
quences and characterization of candidates based on dif-
ferent criteria. In addition, this approach is of particular
interest for difﬁcult or low abundance targets, such as
proteins isolated from gels in the course of proteomic
projects, that are not readily available in sufﬁcient
quantities to support screening campaigns (17,34).
A current limitation worth discussing, is that regions of
the VH and VL chains were sequenced independently pre-
venting a direct analysis of individual clones that are
deﬁned by a combination of VHCDR3 and VLCDR3 se-
quences along with the frameworks in which they have
been inserted. The observed parallel increase in frequency
of certain VHCDR3 and VLCDR3 provides indirect evidence
for enrichment of clones bearing both CDRs. We
demonstrated that the VHCDR3 sequence information is
sufﬁcient to rescue clones of interest, however, the
approach could be further improved by using paired-end
sequencing to reconcile VHCDR3 and VLCDR3 information
(35). In addition, new sequencing reagents allowing for
longer reads will also support a better coverage of the
VLCDR3 sequences and allow VL family assignment.
It is clear that the selection of antibody CDR sequences
is target dependent. However it remains to be fully
elucidated whether there is a preferential usage by the
immune system of certain variable gene families, CDR
lengths and canonical structures for deﬁned target
classes (haptens, carbohydrates, peptides or proteins)
(24,36,37). In this study, we observed that VH families
were differentially enriched during selection against two
protein targets. Comprehensive sequence analysis of selec-
tion rounds against different target classes may provide
new insights into the composition of immune repertoires
and allow for better and potentially more focused library
designs (38).
The implications of NGS for in vitro display and selec-
tion of polypeptide variants will be many and can be
widely applied to the study of molecular interactions
(39). In the context of antibody discovery, they range
from library quality control and improvement to target
speciﬁc sequence evolution and better understanding of
immunoglobulin repertoires. Among these, the possibility
of by-passing upfront screening will streamline in vitro se-
lection approaches, signiﬁcantly increasing relevant
output and thereby facilitating both fundamental and
applied research.
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